Loading…
NewcelX Ltd.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in NCEL.
▼ -99.7% over 5Y.
today you would have $2.95▼ -99.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $1.90 | $21.10 | $236.00 | $516.00 | $444.00 | |
| P/E | — | 0.9x | 8.7x | 208.8x | — | — |
| P/B | 33.2x | 1.3x | — | — | 376.9x | 33.2x |
| EPS | $2.16 | $2.43 | $1.13 | -$335.20 | -$400.00 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BIVIBiovie Inc | $2.16 | — | 1.6x | — | -150.76% | $18.25M |
| PTNPalatin Technologies Inc | $10.48 | 95.3x | 1.8x | — | -297.24% | $18.65M |
| KTTAPasithea Therapeutics Corp. | $0.56 | — | 0.4x | — | -65.49% | $18.71M |
| PMIPicard Medical, Inc. | $8.80 |
NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.
Company description provided by Yahoo Finance.
| ROE | -2202.50% | -114.48% | — | — | -14860.97% | -2202.50% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 10.5x |
| — |
| — |
| $18.07M |
| LPCNLipocine Inc. | $2.17 | — | 0.8x | — | -60.94% | $17.89M |
| TPSTTempest Therapeutics, Inc. | $1.06 | — | 18.6x | — | -931.14% | $17.53M |